Medicure is a specialty pharmaceutical company established in 1997. The Company’s vision is to become a leading specialty pharmaceutical company in the commercialization and development of unique small molecule pharmaceuticals in the cardiovascular and neurological fields for unmet medical needs. AGGRASTAT® - US GP IIb/IIIa inhibitor market - $450 million (AGGRASTAT® + two competitors) TARDOXALTM – in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet need Medicure’s core focus is on the U.S. commercial sales of its FDA approved small molecule, AGGRASTAT. Acquired in 2006, AGGRASTAT is experiencing renewed interest from hospitals and clinicians in the U.S. due to its compelling clinical and economic evidence. The Company has an experienced commercial team in the U.S. dedicated exclusively to the marketing of AGGRASTAT. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous transluminal coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction (MI), or refractory ischemia/repeat cardiac procedure. Medicure opportunistically looks at small molecule development opportunities and currently has development programs in the neurology and cardiology fields. For additional information, health care professionals can visit the AGGRASTAT website.